ADVANCED SOLID TUMORS

This early-stage trial tests an experimental drug called E303 in people with advanced solid tumors that have not responded to standard treatments. The drug is designed to target and attack cancer cells while sparing healthy ones. The main goals are to check safety and see if the …

This study tests whether combining experimental RAS(ON) inhibitors with ivonescimab (an immunotherapy) can shrink or control advanced solid tumors that have a RAS mutation. About 370 adults with cancers like non-small cell lung cancer or colorectal cancer will receive these drugs…

This early-stage trial tests a new drug called YL211 in 155 people with advanced solid tumors who have no standard treatment options left. The study has three parts: first, finding a safe dose; then, confirming that dose; and finally, testing how well it works. The main goals are…

This early-phase trial is testing a new drug called PHST001, which helps the immune system attack cancer cells by blocking a protein called CD24. The study will first test PHST001 alone, then in combination with standard chemotherapy, in adults with advanced solid tumors (includi…

This study tests an experimental oral drug called NTS071 in adults with advanced solid tumors that have a specific change in the TP53 gene (Y220C mutation). The trial has two parts: first, finding a safe dose, and then checking if the drug can shrink tumors. About 220 people who …

This early-stage trial tests an oral drug called GS-2426 in people with advanced solid tumors that lack a gene called MTAP. The main goals are to check safety, find the best dose, and see how the body handles the drug. About 174 adults whose cancer has not responded to standard t…

This study tests an experimental mRNA therapy called mRNA-4359, given alone or with standard immunotherapy drugs, in people with advanced solid tumors (like melanoma, lung cancer, or colorectal cancer). The main goals are to find a safe dose and see if the treatment can shrink tu…

This study tests OTP-01, a new drug that targets two cancer pathways (PD-1 and VEGFR2) at once, in 170 adults with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find the best dose, check safety, and see if the drug can shrink tum…

This study tests a new daily pill, ETX-636, for people with advanced solid tumors (including breast cancer) that have a specific genetic change called PIK3CA. The trial has two parts: first, finding a safe dose of ETX-636 alone or with another drug (fulvestrant); second, checking…

This early-phase study tests a new drug, BG-C477, in about 310 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. The study is open-label, meaning ev…

This early-stage study is testing a new drug called calderasib (MK-1084) in people with advanced solid tumors that have a specific KRAS G12C mutation. The drug is given alone or combined with other cancer treatments. The main goals are to check safety and find the right dose. Abo…

This phase 1 trial tests an experimental drug, DXC006, in people with advanced solid tumors (like small cell lung cancer and neuroblastoma) or blood cancers (like multiple myeloma) who have not responded to standard treatments. DXC006 is an antibody-drug conjugate designed to del…

This study tests whether combining two drugs, YL201 and ivonescimab, can safely shrink tumors in people with advanced solid cancers, including lung cancer. About 260 adults whose cancer has not responded to other treatments will receive the combination. The goal is to find the be…

This early-stage trial is testing an experimental drug called MK-0472, alone or combined with the immunotherapy Keytruda or another experimental drug MK-1084, in people with advanced or metastatic solid tumors. The main goals are to check safety, find the right dose, and see how …

This early-phase study is testing a new drug called OVV-01 in 18 people with advanced solid tumors that have not responded to standard treatments. The drug is given either through a vein or directly into a tumor. The main goal is to check safety and find the right dose, while als…

This study tests a new biologic drug, CM518D1, in people with advanced solid tumors that have not responded to standard treatments. The trial has two phases: first, to find the safest dose and check for side effects, and second, to see if the drug can shrink tumors. About 434 par…

This early-phase trial tests a new drug called metarrestin in people with advanced solid tumors that have spread (metastasized). The goal is to find a safe dose and see if it can shrink tumors. The study includes adults with pancreatic, breast, or other solid tumors, and children…

This study tests a new way to give the drug rilvegostomig as a shot under the skin instead of through an IV. It is for adults with advanced solid tumors who have already tried standard treatments. The goal is to find a dose that works as well as the IV version and to check for si…

This early-stage trial tests a new drug called M7437 in people with advanced solid tumors that have not responded to standard treatments. M7437 is an antibody-drug conjugate designed to deliver chemotherapy directly to cancer cells that have a specific marker (Ly6E). The study ai…

This early-phase trial tests an oral drug called ALTA3263 in about 448 adults with advanced solid tumors (like pancreatic, lung, or colorectal cancer) that have a KRAS mutation. The main goals are to check safety, find the right dose, and see how the body processes the drug. Part…

This early-stage study is testing an experimental oral drug, VVD-133214, in people with advanced solid tumors that have specific genetic features (MSI or dMMR). The drug works by blocking a protein that helps these cancers grow. The study will check safety and how well the drug w…

This early-phase study tests a virus (JNJ-87704916) that is injected directly into tumors to kill cancer cells. It is being tested alone and with another drug (cetrelimab) in people with advanced solid tumors who have run out of standard treatments. The main goals are to check sa…

This early-stage trial tests an experimental drug called TEV-56278, alone or with the immunotherapy pembrolizumab, in 240 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see if the drug…

This early-stage trial tests a new drug called PHN-012 in people with advanced colon, pancreatic, or lung cancer that has stopped responding to standard treatments. The drug is an antibody-drug conjugate, designed to deliver a powerful cancer-killing agent directly to tumor cells…

This early-phase study tests a new drug called JNJ-87890387 in people with advanced solid tumors that have spread or cannot be removed. The drug is designed to help the immune system attack cancer cells. The main goals are to find a safe dose and to check for side effects. About …

This Phase 2 trial tests an oral drug called BAY 2927088 (sevabertinib) in about 111 adults with advanced solid tumors that have HER2 gene mutations. The drug aims to block the abnormal HER2 protein and stop cancer growth. Participants take a 20 mg tablet daily in 3-week cycles u…

This early-phase trial is testing a new oral drug called RMC-5127, alone or combined with other drugs, in adults with advanced solid tumors that have a specific KRAS G12V mutation. The study includes people with lung, colorectal, and pancreatic cancers who have already tried stan…

This early-stage trial is testing a new antibody called GEN1079 in people with certain advanced solid tumors. The study has three parts: first, finding a safe dose; then refining the dose; and finally, checking if the drug shrinks tumors. About 121 participants will receive the a…

This early-phase trial tests an experimental oral drug called ST-01156 in adults with advanced solid tumors that have spread or cannot be removed by surgery. The drug works by breaking down a protein inside cancer cells. The main goals are to find a safe dose and check for side e…

This early-stage study tests a new drug called navlimetostat in 32 Japanese and Chinese patients with advanced solid tumors that have a specific genetic change (MTAP deletion). The main goal is to check the drug's safety and how the body processes it. Participants must have tumor…

This study tests an experimental drug called RMC-9805, taken as a pill, in adults with advanced solid tumors (such as lung, colorectal, or pancreatic cancer) that have a specific mutation in the KRAS gene called G12D. The drug is given alone or in combination with another oral dr…

This early-phase trial tests a new biologic drug called SBO-154 in 177 people with advanced solid tumors that have not responded to or cannot tolerate standard treatments. The main goals are to check safety, find the right dose, and get a first look at whether the drug can shrink…

The TAPUR study is testing a wide range of targeted cancer drugs in people with advanced solid tumors, lymphoma, or multiple myeloma whose tumors have specific genetic changes. The goal is to see if matching drugs to these genetic variants can shrink tumors or stop them from grow…

This early-phase study tests a new drug called GS-0201, given alone or with another cancer drug (sacituzumab govitecan), in adults with advanced solid tumors that have not responded to other treatments. The main goals are to check safety, find the best dose, and see how the body …

This trial tests a new drug called TUB-030 in adults with advanced solid tumors, including head and neck, lung, and breast cancers. The goal is to find the safest and most effective dose. Participants receive the drug every three weeks and are monitored for side effects and tumor…

This study tests an experimental drug called SHR-A1904 in 83 people with advanced solid tumors, including stomach and pancreatic cancers that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tum…

This study tests a new drug, ALK201, for the first time in people with advanced solid tumors that have not responded to other treatments. The goal is to find a safe dose and see if the drug can shrink tumors. About 202 adults aged 18 to 75 will take part. The study is currently r…

This early-phase study is testing a new treatment called KXV01 for people with advanced solid tumors, including sarcomas, who have no other options. The therapy uses a patient's own immune cells, modified with a virus to recognize and attack their specific tumor. The main goal is…

This study tests a new drug, SKB103, in people with advanced solid tumors who have run out of standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors or slow their growth. About 277 adults aged 18 to 75 will take part.

This early-phase trial tests AMT-676, a drug designed to seek out and destroy cancer cells that carry a protein called CDH17. It is given intravenously to 24 adults with advanced solid tumors (such as colorectal, gastric, or pancreatic cancer) that have not responded to prior tre…

This study is for people with advanced solid tumors who have a specific gene change (KRAS G12C) and are already doing well on sotorasib (with or without panitumumab) from a previous Amgen trial. It allows them to keep receiving the treatment while doctors monitor safety and side …

This early-stage study tests a new drug called SIGX1094R in about 102 adults with advanced solid tumors who have no standard treatment left. The main goals are to check the drug's safety, find the right dose, and see how it affects tumors. Researchers will also look at how food c…

This study is testing an experimental oral drug called RMC-6236 in adults with advanced solid tumors (like lung, colorectal, or pancreatic cancer) that have specific RAS mutations. The main goals are to find safe doses and understand side effects. About 754 participants will take…

This study tests a new treatment called EB-NK-301, which uses specially engineered immune cells (CAR NK cells) to target a protein called TROP2 found on many solid tumors. The trial enrolls 60 adults with advanced or metastatic cancers that have not responded to standard treatmen…

This early-stage trial tests whether injecting specially reprogrammed immune cell particles (exosomes) directly into tumors is safe for people with advanced solid tumors who have run out of standard options. Nine adults aged 18-65 will receive four injections over eight weeks. Th…

This study tests a new drug called SHR-9839, given with other cancer treatments, for people with advanced solid tumors that have not responded to standard therapy. The goal is to see if the combination is safe and can shrink tumors. About 156 adults aged 18-75 with certain cancer…

This early-phase trial is testing a new drug, SKB500, in 180 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see how the body processes it. Researchers will also look for ear…

This early-stage trial tests a new drug called SKB518 in 150 adults with advanced solid tumors that have stopped responding to standard treatments. The main goals are to check safety, find the right dose, and see if the drug can shrink tumors. Participants receive the drug every …

This early-stage study is testing an experimental drug called MK-6204 in about 90 adults with advanced solid tumors (such as colorectal, lung, or stomach cancer) that have not responded to standard therapies. The main goals are to check the drug's safety and find the right dose. …

This study is testing a new drug called MK-3120 in people with advanced solid tumors that have spread and cannot be removed by surgery. The main goal is to see if the drug is safe and tolerable. About 270 participants will receive the drug by IV infusion. The study also looks at …

This early-phase trial is testing an experimental drug called SKB445 in 126 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the right dose, and get an early look at whether the drug can shrink tumors. Part…

This early-phase study tests the safety and best dose of SKB315, a drug designed to attack cancer cells with a specific protein called Claudin18.2. About 246 adults with advanced solid tumors that haven't responded to standard treatments will receive the drug. The goal is to see …

This early-phase study tests a new drug called VVD-130037 in people with advanced solid tumors that have stopped responding to standard treatments. The drug aims to activate a protein (KEAP1) to fight cancer. Researchers will check safety, side effects, and whether the drug works…

This study tests a new drug called SKB105 in 256 adults with advanced solid tumors that have not responded to standard treatments. SKB105 is an antibody-drug conjugate designed to deliver chemotherapy directly to cancer cells. The trial will first find the safest dose, then check…

This study tests a new drug called DT-7012, alone or with another cancer drug (an immune checkpoint inhibitor), in 125 adults with advanced solid tumors that have not responded to prior treatments. The goal is to see if the combination is safe and can shrink tumors. It is an earl…

This study tests a new drug called PYX-201 combined with pembrolizumab in people with advanced solid tumors that have not responded to other treatments. The goal is to find safe doses and see if the combination can shrink tumors. About 220 adults with certain cancers like head an…

This study tests a modified herpesvirus (T3011) combined with standard immunotherapy drugs (PD-1/PD-L1 inhibitors) in people with advanced solid tumors that have not responded to other treatments. The goal is to see if the combination is safe and can shrink tumors. About 68 parti…

This early-phase trial is testing a new treatment called NK521 for people with advanced solid tumors that have spread and caused fluid buildup in the belly (malignant ascites). The treatment uses a person's own natural killer (NK) cells that have been gene-edited to better attack…

This study tests a new drug called CKD-703 in people with advanced solid tumors or non-small cell lung cancer that has a specific protein (c-Met). The drug is designed to attach to cancer cells and release chemotherapy directly inside them, aiming to kill the cancer while reducin…

This early-stage trial tests MGC028, a drug that delivers a cancer-killing agent directly to tumor cells. About 124 adults with advanced lung, bile duct, pancreatic, or colorectal cancers that have stopped responding to standard treatments will receive the drug every three weeks.…

This study tests an experimental drug called REGN10597, alone or with another drug (cemiplimab), in people with advanced solid tumors like melanoma and kidney cancer. The goal is to see if the treatment is safe and can shrink tumors. About 240 participants will receive the drug i…

This early-stage study tests a new drug called HWS116 in about 56 adults with advanced solid tumors (like colorectal, gastric, or pancreatic cancer) that have stopped responding to standard treatments. The main goals are to check the drug's safety and see if it can shrink tumors.…

This early-stage trial tests a new drug called BGM-2121 in 35 adults with advanced solid tumors that have not responded to standard treatments. The main goal is to check safety and find the right dose. Researchers will also look for early signs that the drug might help control th…

This early-stage trial is testing a new drug called GS-2121, taken as a tablet, alone or with an intravenous drug called zimberelimab, in 154 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, …

This early-stage study tests a new drug called HDM2024 in 63 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check if the drug is safe and to see if it can shrink tumors. Participants receive the drug once every three weeks,…

This study tests a new drug called CS2009, a tri-specific antibody that targets three proteins (PD-1, VEGFA, and CTLA-4) to fight advanced solid tumors. The trial has two phases: first, finding the safest dose, then expanding to see how well it shrinks tumors. About 660 adults wi…

This study tests a new drug called XNW28012 in people with advanced solid tumors (pancreatic, ovarian, cervical, or colorectal cancers) that have stopped responding to standard treatments. The trial has two parts: first, finding a safe dose, then expanding to see if the drug shri…

This early-stage trial is testing a new drug called TGW101 in people with advanced solid tumors that have not responded to other treatments. TGW101 is given in two parts: an antibody-drug conjugate and a chemical trigger that activates it. The main goal is to check safety and fin…

This early-stage trial is testing a new drug called FS-8002, alone or combined with other treatments, in 66 people with advanced solid tumors that have stopped responding to standard care. The main goals are to check safety, find the right dose, and get a first look at whether th…

This study tests a new drug called EIK1005, alone or with another drug (pembrolizumab), in people with advanced solid tumors that have not responded to other treatments. The goal is to find a safe dose and see if the drug shrinks tumors. About 160 adults with certain cancer types…

This study tests a new drug called marlotamig (REGN7075) alone or with cemiplimab (Libtayo) and sometimes chemotherapy in people with advanced solid tumors. The goal is to find the safest dose and see if the combination can shrink tumors. About 933 participants are being recruite…

This early-stage trial is testing NK042, a ready-made natural killer cell therapy made from healthy donors, in 76 people with advanced solid tumors that have not responded to standard treatments. Participants first receive chemotherapy to prepare their immune system, then an infu…

This early-phase study tests an experimental drug called WJB001 in people with advanced solid tumors who have no standard treatment options left. The trial has three parts: first, finding a safe dose; second, checking how well that dose works; and third, testing it in specific tu…

This early-stage study tests a new drug called HRS-3802 in 100 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. Participants will receive the drug …

This study tests whether giving cancer patients a targeted therapy that matches a specific gene change in their tumor can help shrink or control the cancer. It includes 720 adults with advanced solid tumors, multiple myeloma, or non-Hodgkin lymphoma who have no standard treatment…

This study tests an experimental drug called VIB305 in people with advanced solid tumors that have not responded to or cannot be treated with standard therapies. The trial has two parts: first, finding the safest dose, and then testing that dose in more patients to see if it shri…

This early-phase trial tests a new drug called VVD-159642, which targets specific cancer-driving proteins. It is given alone or with other drugs (sotorasib or trametinib) to people with advanced solid tumors that have certain genetic changes. The main goals are to check safety, f…

This early-phase study tests a new drug, ASP1002, in adults with advanced solid tumors that have high levels of a protein called claudin 4. The main goals are to check the drug's safety, find the best dose, and see how well people tolerate it. Participants receive the drug throug…

This study tests a new medicine, SNV4818, in about 320 adults with advanced solid tumors that have a specific genetic change (PIK3CA mutation) and have not responded to other treatments. The main goals are to check safety and find the best dose, either alone or with other cancer …

This early-stage study tests a new drug called Hemay181 in 24 people with advanced solid tumors that have not responded to standard treatments or have no standard options. The main goal is to see if the drug can shrink tumors and to check for side effects. Participants will recei…

This study is testing an experimental oral drug called ATX-295 in people with advanced solid tumors, including ovarian cancer, that have not responded to standard treatments. The main goal is to find a safe and tolerable dose and to see if the drug can shrink tumors. About 90 par…

This early-phase study tests a new cell therapy called GK01 in 10 people with advanced lung or esophageal cancer that no longer responds to standard treatments. The main goal is to check safety and how the body handles the therapy. Researchers will also look for early signs of tu…

This early-phase trial tests a new drug called 177Lu-RAD202, which is a radioactive antibody designed to seek out and deliver radiation directly to HER2-positive cancer cells. The study involves 30 adults with advanced solid tumors that have not responded to standard treatments. …

This early-stage study tests the drug pralatrexate in 24 adults with advanced cancer and varying levels of liver function. The goal is to see how the body processes the drug and to find the right dose for people with mild, moderate, or severe liver impairment. Participants receiv…

This study tests a new drug called GW5282 in people with advanced solid tumors that have not responded to standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors. About 203 adults will take part in this early-phase trial.

This early-stage trial is testing a new drug called BAT8008 in people with advanced solid tumors that have not responded to standard treatments. The drug is designed to target a protein called Trop2 found on many cancer cells. The main goals are to check safety, find the best dos…

This study tests a new drug called SPR1020 in adults with advanced solid tumors that have not responded to standard treatments. The drug is designed to target cancer cells with specific genetic changes (BRCA or HRR mutations) and may also reach brain tumors. The goal is to find a…

This early-stage study tests a new drug called CKD-512, given alone or with an immunotherapy (pembrolizumab), in people with advanced solid tumors that have not responded to standard treatments. The main goals are to find a safe dose and check for side effects. About 60 participa…

This study tests an experimental drug called BMS-986482, alone or combined with other cancer drugs, in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and find the right dose. About 413 adults will take part. Th…

This early-phase trial tests an experimental oral drug called HDM2006 in 48 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see if the drug shows any signs of shrinking tumors. Particip…

This study tests a new biologic drug called ASKG915, given alone or with standard chemotherapy, in about 594 people with advanced solid tumors that have stopped responding to other treatments. The main goals are to check safety and find the best dose. The trial is currently recru…

This early-stage trial is testing an experimental drug called SIM0505 in adults with advanced solid tumors that have not responded to standard treatments. The study aims to find a safe dose and check for any early signs that the drug shrinks tumors. About 414 participants will re…

This study tests a new drug called WEF-001 in people with advanced solid tumors that have a KRAS mutation, including pancreatic, colorectal, and lung cancers. The goal is to check the drug's safety and how well it shrinks tumors. About 110 adults who have already tried standard t…

This study tests an experimental drug called MRG006A in 343 adults with advanced solid tumors that have spread or cannot be removed. The drug is given through a vein. The main goals are to find the safest dose and see if the drug can shrink tumors. The trial is currently recruiti…

This early-phase study tests a new drug called FORX-428 in about 40 adults with advanced solid tumors that have certain gene changes (like BRCA1/2 mutations). The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors or slow their growth. …

This early-phase trial is testing a new therapy called Meta10-TIL for people with advanced solid tumors that have not responded to standard treatments. The therapy uses a patient's own immune cells (tumor-infiltrating lymphocytes) that are modified in the lab to better fight canc…

This study tests an experimental pill called WJ22096 in about 20 adults with advanced solid tumors (like lung, colon, or pancreatic cancer) who have run out of standard options. The goal is to find a safe dose and see if the drug can shrink tumors. Participants take the pill by m…

This study tests an experimental drug called JAB-23E73, taken as a pill, in adults with advanced solid tumors that have a KRAS alteration. The trial has three parts: first finding a safe dose, then optimizing it, and finally checking if the drug shrinks tumors in certain cancers …

This early-stage trial tests a new drug called HS-20122 in people with advanced solid tumors who have no other treatment options. The study aims to find the safest dose and check for side effects. Up to 1,050 participants will receive the drug intravenously and be monitored close…

This early-phase trial tests an experimental drug called ABX-001, given alone or with the immunotherapy pembrolizumab, in 27 people with advanced solid tumors who have no standard treatment options left. The main goal is to check safety and find the right dose, while also looking…

This study tests an experimental drug called SPH4336, given alone or with another drug (cadonilimab), in people with advanced solid tumors that cannot be removed by surgery. The goal is to see if the treatment can slow or stop cancer growth. About 63 participants will take part i…

This study tests a new drug called FL115 combined with an immunotherapy (PD-1 blocker) in 130 people with advanced solid tumors that have not responded to standard treatments. The trial has two phases: first to find the safest dose, then to see how well the combo works against di…

This early-phase trial is testing a new drug, SIBP-A19, in 156 people with advanced solid tumors who have no other standard treatment options. The main goals are to check the drug's safety, find the best dose, and look for early signs that it might shrink tumors. The drug is give…

This early-stage trial tests a new drug called GenSci143 in 180 adults with advanced solid tumors that have not responded to standard treatments. The study aims to find a safe dose and check for any signs that the drug can control tumor growth. Participants receive the drug by in…

This study tests a new tablet called ABP1011T in people with advanced solid tumors, including small cell lung cancer and others like esophageal or bladder cancer. Participants take one pill daily in 21-day cycles. The goal is to see if the drug can shrink tumors and how safe it i…

This early-stage trial tests an experimental tablet called ZX-8177 in 80 Chinese patients with advanced solid tumors that have not responded to standard treatments. The study aims to find the safest dose and check for any signs that the drug can shrink tumors. It is a first step …

This early-stage study tests a new drug, HW071021, in 76 adults with advanced solid tumors (like lung, colorectal, or pancreatic cancer) that have spread or come back. The main goals are to check the drug's safety, find the right dose, and see if it helps shrink tumors. Participa…

This early-stage study tests a new drug called GenSci139 in about 280 people with advanced solid tumors that have spread. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. The study is currently recruiting participants.

This early-stage study tests a new drug called GenSci140 in people with advanced solid tumors that have not responded to other treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. About 170 adults in China will take part,…

This study tests an experimental drug, YL205, in 252 people with advanced solid tumors that have spread or cannot be removed by surgery. The drug is given by IV every three weeks. The main goals are to check safety, find the right dose, and see if it helps shrink tumors. This is …

This early-phase study tests a new drug called INCA33890 in about 408 adults with advanced or metastatic solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors or slow their g…

This early-stage trial is testing a new drug called BTM-3566 in 30 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to find safe doses and understand side effects. Participants take the drug for 7 days on and 7 days off, and res…

This early-phase trial tests whether combining an experimental drug (AT1019), targeted radiation (SBRT), and an immunotherapy (PD-1 inhibitor) is safe for people with advanced solid tumors. About 12 participants will receive the combination and be monitored for side effects and t…

This study tests a new drug called BMS-986490, alone or with bevacizumab, in people with advanced solid tumors that have a specific marker (CEACAM5). The goal is to see if the treatment is safe and works against these cancers. About 360 participants will take part in this early-s…

This early-phase trial tests a personalized therapy for people with advanced solid tumors that have not responded to standard treatments. Doctors take immune cells from a sample of the patient's tumor, grow them into large numbers in a lab, and infuse them back into the patient. …

This study tests a new drug called SHR-1826 combined with other cancer treatments for people with advanced solid tumors that have not responded to standard therapy. The goal is to find the safest dose and see if the combination can shrink tumors or slow their growth. About 876 ad…

This study tests a new drug called MB0151 in adults with advanced solid tumors, including certain lung, breast, and neuroendocrine cancers. The goal is to check the drug's safety and see if it can shrink or control tumors. About 156 participants will receive the drug intravenousl…

This study tests a new drug called HRS-6768 in people with advanced solid tumors that have not responded to standard treatments. The trial has two phases: the first checks safety and the best dose, and the second looks at whether the drug can slow tumor growth. About 84 participa…

This early-stage trial is testing a new drug called PAS-004 in people with advanced solid tumors that have certain gene mutations (RAS, NF1, or RAF). The main goal is to see how safe the drug is and what side effects it causes. About 48 participants will take the drug by mouth da…

This early-phase study tests an experimental tablet, JMKX005425, in people with advanced solid tumors that have high microsatellite instability or mismatch repair deficiency. The main goals are to check the drug's safety and find the right dose. About 102 participants will take t…

This study tests a combination of sirolimus (a targeted therapy) with several antibody-drug conjugates (ADCs) in people with advanced solid tumors that have spread or cannot be removed. The goal is to find a safe dose and see if the combo can shrink tumors. About 444 participants…

This early-stage study tests a new drug, ACR246, in about 77 adults with advanced solid tumors that have stopped responding to standard treatments. The main goal is to find a safe dose and check for side effects. Researchers will also measure how the drug moves through the body a…

This study tests an experimental drug called DB-1311/BNT324 in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. About 862 adults will take pa…

This study tests an experimental drug called GFH375 in people with advanced solid tumors that have a specific genetic change (KRAS G12D). The goal is to see if the drug is safe, tolerable, and can shrink tumors. About 407 adults aged 18 to 75 with advanced cancers like lung or pa…

This early-stage trial tests a new daily pill called TYRA-430 in 100 adults with advanced liver cancer or other solid tumors that have specific genetic changes. The main goals are to find the safest dose and check for side effects. Researchers will also look for signs that the dr…

This early-stage study tests a new tablet called GEN-725 in 48 adults with advanced solid tumors that have stopped responding to standard treatments. The main goals are to check the drug's safety, how the body processes it, and whether it can shrink tumors. Participants must be b…

This early-stage study is testing a new drug called SHR-3821 in 162 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. Participants will receive the…

This early-stage study tests a new drug called FP008 in 108 adults with advanced solid tumors that have not responded to other treatments. The main goal is to check the drug's safety and find the right dose. Researchers will also look at how the drug works in the body and whether…

This study tests a new drug called LCB84, which targets a protein (TROP2) found on many cancer cells and delivers a toxic payload directly to them. It is being tested alone and together with an immunotherapy drug (anti-PD-1) in 300 people with advanced solid tumors that have not …

This early study tests a new combination therapy for people with advanced solid tumors that have stopped responding to standard treatments. The therapy uses a modified virus (hV01) designed to infect and kill cancer cells while boosting the immune system, plus an immunotherapy dr…

This study tests a new drug called HRS-4642 combined with other anti-cancer agents in people with advanced solid tumors that have a KRAS G12D mutation. The trial has two phases: first to find the safest dose, then to see how well the combination works. About 118 adults aged 18-75…

This early-phase trial is testing a new therapy called Meta10-TIL for people with advanced solid tumors that have not responded to at least one prior treatment. The therapy uses a patient's own tumor-fighting immune cells, which are modified in the lab to work better, and then gi…

This study tests a new drug called YL202 combined with other anti-cancer medicines (toripalimab or furmonertinib) in people with advanced solid tumors, including breast and lung cancer. The goal is to find safe doses and see if the combination shrinks tumors. About 414 adults age…

This early-stage trial tests a new drug called OKI-219 in people with advanced solid tumors or breast cancer that have a specific PI3K gene mutation. The drug is designed to block the mutant protein and slow cancer growth. Up to 200 participants will receive OKI-219 alone or comb…

This early-phase study tests a new oral drug called SYN818 combined with olaparib in 110 adults with advanced solid tumors, including ovarian and breast cancers that have BRCA mutations or related DNA repair problems. The main goals are to find a safe dose and check for side effe…

This early-stage trial is testing an experimental drug called AMT-253 in about 96 people with advanced melanoma or other solid tumors that have not responded to standard treatments. The study has two parts: first, finding the safest dose, and then expanding to see how well the dr…

This early-phase trial tests a new drug called FID-022 in 24 adults with advanced solid tumors that have not responded to standard treatments. The main goal is to find a safe dose and check for side effects. The drug contains two active components, including irinotecan, which is …

This early-phase study tests a new drug called AK146D1 in 200 adults with advanced solid tumors that have worsened after standard treatments. The drug is designed to attach to two proteins (Trop2 and Nectin4) on cancer cells and deliver a toxic payload. The main goals are to chec…

This early study is testing a new imaging agent called FL-261 in 12 people with advanced cancers like lung, colorectal, or head & neck cancer. The agent targets a protein called c-MET that is often found on cancer cells. Researchers want to see if FL-261 scans can safely and accu…

This study tests whether wearing a compression stocking on one foot during antibody-drug conjugate (ADC) infusions can prevent peripheral neuropathy (nerve damage causing numbness or pain). Fifty-eight advanced cancer patients will wear a stocking on their left foot only, while t…

This study tests whether a simple card game, the Go Wish Game, can help people with advanced blood cancers or solid tumors discuss their end-of-life priorities with doctors. About 75 patients will use the cards to sort what matters most to them, then complete an advance care plan…

This early-phase study is looking at how a new drug called rezatapopt affects the way the body processes four common medications (metformin, rosuvastatin, repaglinide, and midazolam) in people with advanced solid tumors that have a specific genetic mutation (TP53 Y220C). The goal…

This study looks at how the antifungal drug itraconazole changes the levels of the cancer drug HS-20093 in the body. It involves 18 adults with advanced solid tumors who have not responded to or cannot tolerate standard treatments. The goal is to measure drug concentrations over …